Hepatitis C Donor Viremic Cardiac Transplantation: A Practical Approach.
Patients with end-stage heart failure eligible for orthotopic heart transplantation (OHT) exceed the number of available donor organs. With highly effective Hepatitis C Virus (HCV) antiviral therapy now available, HCV+ organs are increasingly utilized. We seek to describe our experience with patients receiving HCV viremic organs as compared to non-HCV transplant recipients. Our center began utilizing HCV hearts in February 2018. We retrospectively reviewed baseline demographics, laboratory data, and outcomes for those undergoing OHT with majority being from a viremic HCV donor. Twenty three of 25 HCV recipients received hearts from NAT + donors with 22 of 23 seroconverting within 7 days. Fifteen recipients have completed HCV treatment, with the longest duration of follow up being 13 months. No differences in rates of rejection, hospitalizations or death were seen between non-HCV and HCV transplant patients. With the advent of available direct acting antivirals (DAA), viremic HCV hearts provide an opportunity to increase organ availability. Moreover, treatment for HCV in the setting of immunosuppression is well-tolerated and results in sustained viremic response. Viremic, discordant HCV OHT can be performed in a safe and effective manner utilizing a systematic, multidisciplinary approach without an effect on short-term outcomes.